Fig. 7: HU-F-AIM study design. | Leukemia

Fig. 7: HU-F-AIM study design.

From: Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)

Fig. 7

ELN European LeukemiaNet, EOS end of study, EOT end of treatment, HU hydroxyurea, PV polycythemia vera, WHO World Health Organization. a Visits during the treatment period will be scheduled every 2 weeks for the first 3 months, then every 6 weeks until up to month 15. b Assessment of HU-RES/intolerance is based on the modified ELN criteria [23]. If a participant shows HU-RES/intolerance during the treatment period or discontinue the treatment for any reason, an EOT visit will be scheduled, and the participant will enter the follow-up period (i.e. 30-day safety follow-up visit and 3-month follow-up visit [EOS]). If no HU-RES/intolerance is observed during the treatment period of maximum 15 months, then the participant will complete the EOT visit followed by a 30-day safety follow-up visit (EOS).

Back to article page